Craig Koch has been appointed as Velocity’s new Executive Vice President, Europe, to spearhead the next phase of growth across the region. His appointment underscores the company’s long-term commitment to Europe. Previously serving as EVP, Global Head of Sales, Craig has been with Velocity since 2019. He is now relocating to Europe to provide hands-on … Read more
Brandon Essink, MD, CPI, is the lead author of study results exploring a next-generation flu vaccine for adults 50+. The published results highlight the potential for combining cell-based approaches and adjuvants to enhance immunogenicity relative to standard flu vaccines on the market. Title: “A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent … Read more
Congratulations to our Annapolis, MD, site for being recognized as the top U.S. enroller in a Phase 3 respiratory trial. Established in partnership with Luminis Health, this site also marked Velocity’s entry into oncology in the U.S.
Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve vaccine trials worldwide. Vote now: https://terrapinn-awards.evessiocloud.com/vieawards2025/en/page/public-vote-vie-awards We look forward to seeing … Read more
Congratulations to our team in Staszów, Poland, and Katarzyna Wawrzyniec-Lis, MD, for being the top global enroller for Boehringer Ingelheim’s Phase 3 cardiovascular safety study for patients with obesity! Velocity is supporting this study at more than 20 sites across the U.S., Poland, and Germany.
Thank you to SCOPE Summit for recognizing Velocity at the 2025 Site Innovation Award presentation! Our presentation focused on the way VISION is enhancing trial accessibility for participants worldwide. Now available in four countries and four languages, the VISION Engage mobile app has been downloaded more than 100,000 times. To date, VISION has supported: • … Read more
Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ global sites. The collaboration addresses a critical industry challenge: the double enrollment of participants in multiple studies … Read more
In a recent global trial, Velocity sites enrolled participants 50% faster than the average trial site. Additionally, Velocity supported the trial with over 30 research sites across several countries. In another recent trial, Velocity’s 20 sites outpaced average trial site enrollment rate by nearly 80%. These achievements illustrate the power of Velocity at Scale — … Read more
We’re proud to announce that Velocity is a founding member of the newly launched Association of MultiSite Research Corporations (AMRC)! This innovative trade association unites 14 leading organizations to address the systemic challenges in clinical trials and drive meaningful change across the industry. With over 80 fully integrated research sites across the U.S. and Europe … Read more
Congratulations to Paul Evans for being named one of the Top 50 Healthcare Technology CEOs of 2024! With Paul’s leadership, Velocity continues to redefine how clinical trials are conducted — leveraging VISION technology, centralization, and global site integration to accelerate drug development. His recognition by The Healthcare Technology Report is a nod to his vision … Read more